This document provides an extensive analysis of the molecular diagnostics market in France, including forecasts of test volumes and reagent sales by application from 2012-2022. It details the major technologies, products, suppliers, and opportunities in the market. The report is 850 pages and provides comprehensive information on DNA sequencing, probe technologies, detection methods, instrumentation, emerging applications in infectious disease, cancer, and genetic testing, as well as profiles of key companies and their products, strategies, and sales. It sells for a single-user license of $5,900.
Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
This 850-page report provides a comprehensive analysis of the Italian molecular diagnostics market, including major issues, trends, technologies, test categories, suppliers, and business opportunities. It forecasts test volumes and reagent sales for infectious diseases, genetic diseases, cancer, forensic testing, and other areas. The report profiles leading suppliers and identifies over 60 market opportunities. It also discusses alternative market strategies, barriers, and competitive landscapes. An executive summary analyzes the Italian business environment and market structure.
Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
This 860-page report provides a comprehensive analysis of the molecular diagnostics market in Spain, including key trends, technologies, major applications and suppliers. It covers topics such as DNA sequencing, probe technologies, detection methods, instrumentation, emerging applications in oncology, infectious diseases and pharmacogenomics. The report also identifies over 60 specific business opportunities and strategies for companies to enter the Spanish molecular diagnostics market.
US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...ReportsnReports
This 880-page report provides an extensive analysis of the US molecular diagnostics market, including forecasts of test volumes and reagent sales for various applications through 2022. It reviews DNA sequencing and probe technologies, detection methods, automated instrumentation, and profiles major suppliers. The report also identifies over 60 business opportunities in instruments, tests, software, and auxiliary products and discusses strategies for market entry.
Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
This 860-page report provides a comprehensive analysis of the Japanese molecular diagnostics market, including major trends, technologies, applications, and key players. It forecasts test volumes and reagent sales for infectious diseases, genetic diseases, cancer, and other applications. The report profiles leading suppliers and identifies over 60 business opportunities in molecular diagnostic instruments, tests, software, and auxiliary products. It also examines market entry barriers, alternative strategies, and concerns for companies operating in this space.
Innovative Molecular Diagnostic Technologies and Emerging MarketsReportsnReports
This document provides a 1050-page report on innovative molecular diagnostic technologies and emerging markets. It explores business and technology trends in major countries and provides forecasts for market size, test volumes, and shares of leading competitors over the next 5-10 years. The report also profiles leading market players, identifies opportunities in product development, and discusses strategies for companies to successfully capitalize on the growing molecular diagnostics market.
UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...ReportsnReports
This 855-page report provides an extensive analysis of the UK molecular diagnostics market, including forecasts of test volumes and reagent sales for infectious diseases, genetic diseases, cancer, and other applications through 2022. It reviews DNA sequencing and probe technologies, detection methods, automated instrumentation, and profiles major suppliers. The report identifies over 60 market opportunities and provides guidance on business strategies, market entry barriers, and alternative market penetration approaches.
This presentation (in English) made at ONCOTRANS in Besançon on Friday 3rd 2017 reviews the potential for TGF-beta inhibition in hepatocellular carcinoma based on preclinical and clinical data.
Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
This 850-page report provides a comprehensive analysis of the Italian molecular diagnostics market, including major issues, trends, technologies, test categories, suppliers, and business opportunities. It forecasts test volumes and reagent sales for infectious diseases, genetic diseases, cancer, forensic testing, and other areas. The report profiles leading suppliers and identifies over 60 market opportunities. It also discusses alternative market strategies, barriers, and competitive landscapes. An executive summary analyzes the Italian business environment and market structure.
Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
This 860-page report provides a comprehensive analysis of the molecular diagnostics market in Spain, including key trends, technologies, major applications and suppliers. It covers topics such as DNA sequencing, probe technologies, detection methods, instrumentation, emerging applications in oncology, infectious diseases and pharmacogenomics. The report also identifies over 60 specific business opportunities and strategies for companies to enter the Spanish molecular diagnostics market.
US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...ReportsnReports
This 880-page report provides an extensive analysis of the US molecular diagnostics market, including forecasts of test volumes and reagent sales for various applications through 2022. It reviews DNA sequencing and probe technologies, detection methods, automated instrumentation, and profiles major suppliers. The report also identifies over 60 business opportunities in instruments, tests, software, and auxiliary products and discusses strategies for market entry.
Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
This 860-page report provides a comprehensive analysis of the Japanese molecular diagnostics market, including major trends, technologies, applications, and key players. It forecasts test volumes and reagent sales for infectious diseases, genetic diseases, cancer, and other applications. The report profiles leading suppliers and identifies over 60 business opportunities in molecular diagnostic instruments, tests, software, and auxiliary products. It also examines market entry barriers, alternative strategies, and concerns for companies operating in this space.
Innovative Molecular Diagnostic Technologies and Emerging MarketsReportsnReports
This document provides a 1050-page report on innovative molecular diagnostic technologies and emerging markets. It explores business and technology trends in major countries and provides forecasts for market size, test volumes, and shares of leading competitors over the next 5-10 years. The report also profiles leading market players, identifies opportunities in product development, and discusses strategies for companies to successfully capitalize on the growing molecular diagnostics market.
UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...ReportsnReports
This 855-page report provides an extensive analysis of the UK molecular diagnostics market, including forecasts of test volumes and reagent sales for infectious diseases, genetic diseases, cancer, and other applications through 2022. It reviews DNA sequencing and probe technologies, detection methods, automated instrumentation, and profiles major suppliers. The report identifies over 60 market opportunities and provides guidance on business strategies, market entry barriers, and alternative market penetration approaches.
This presentation (in English) made at ONCOTRANS in Besançon on Friday 3rd 2017 reviews the potential for TGF-beta inhibition in hepatocellular carcinoma based on preclinical and clinical data.
Biopharmaceuticals are large molecule drugs made using cells or enzymes, often similar to natural biological compounds. Examples include proteins, peptides, nucleic acids, and gene therapy. The first approved biopharmaceuticals were recombinant human insulin in 1982 and recombinant tissue plasminogen activator in 1986. Today, biopharmaceutical sales reach over $200 billion annually and there are over 300 approved biopharmaceutical drugs on the market. Biopharmaceuticals are mainly produced using bacterial, mammalian, yeast, plant, or animal cells transfected with plasmids containing the gene for the target protein. Purification then isolates the target protein for clinical use.
Dr. maryalice stetler stevenson lymphoma mrdHitham Esam
Flow cytometry can be used to detect minimal residual disease (MRD) in plasma cell neoplasms such as multiple myeloma. It provides both prognostic information and a way to measure response to drug therapies. Several factors are important for obtaining high quality flow cytometry results, including using bone marrow aspirates within 24 hours of collection, lysing red blood cells, acquiring sufficient events, and using standardized staining and gating strategies. Detection of MRD by flow post-treatment is predictive of patient outcomes and can guide clinical decision making.
This document provides an overview of AV Therapeutics, a biotechnology company developing safer and more effective chemotherapeutic agents. Their lead drug candidate, Capridine-β, shows promise for treating prostate cancer. It has demonstrated efficacy against hormone-responsive and non-responsive prostate cancer xenografts in mice, with limited side effects. Capridine-β is a patented anticancer drug that kills prostate cancer cells preferentially over other cell types and has been shown to be more potent than other drugs like taxanes. AV Therapeutics aims to develop Capridine-β as an effective drug-based therapy for prostate cancer with a better safety profile than existing options.
"Familial" versus "sporadic" Intellectual Disability: Contribution of DNA Cop...Maryam Rafati
This document appears to be a PhD thesis presentation by Maryam Rafati at Tehran University of Medical Sciences on February 15, 2012. The presentation aims to determine the genetic causes of familial mental retardation (MR) and whether a different diagnostic approach should be used for familial versus sporadic MR cases. It involves studying 426 sporadic and familial MR patients using techniques such as karyotyping, fragile X testing, subtelomeric and microdeletion/duplication analysis, and array comparative genomic hybridization. The results identified chromosomal abnormalities, syndromes and single gene disorders in 41 patients, demonstrating the utility of genetic testing in familial MR cases.
GPCR ligand screening assay
Monitors the very early activation stage of Frizzled-Receptors of the GPCR group
Our assay can be implemented in a cell-free chemical compound high-throughput target screening. GPCR is the largest known category of molecular targets with verified therapeutic value. Up to 40% of approved drugs are targeted to GPCRs. 25% of the top 200 best-selling drug targets are GPCRs.
Dr. maryalice stetler stevenson b-all mrdHitham Esam
Flow cytometry plays an important role in detecting minimal residual disease (MRD) in B-cell acute lymphoblastic leukemia (B-ALL). Studies by the Children's Oncology Group (COG) determined that a level of >0.01% MRD detected by flow cytometry indicates higher risk and is clinically relevant. The COG assay uses specific antibody panels to identify and quantify residual leukemia blasts in bone marrow samples. The assay was validated across laboratories, showing the same results and prognostic value. Standardized gating strategies and analytical techniques are crucial for accurate and reproducible MRD detection by flow cytometry.
The document evaluates the usefulness of rapid diagnostic tests (RDTs) for diagnosing malaria compared to microscopic examination. It finds that RDTs diagnosed 41 out of 43 total malaria cases in the study, while microscopy only diagnosed 34 cases. RDTs were found to be highly sensitive (96.55%) and specific (71.79%) for detecting Plasmodium falciparum malaria compared to microscopy. The study concludes that RDTs are an effective, rapid and accurate method for diagnosing malaria, especially in cases where immediate diagnosis is needed. RDTs performed better than microscopy and using both tests together provides the best approach for malaria diagnosis.
Poster presentation at the 2016 WORLD GASTROINTESTINAL SYMPOSIUM on tepotinib a selective inhibitor of c-MET by S. Faivre, J.-F. Blanc, P. Merle, A. Fasolo, A. Iacobellis, V. Grando, T. Decaens, J. Trojan, E. Villa, U. Stammberger, R. Bruns, E. Raymond
1Oncology Unit, Beaujon University Hospital, Clichy, France; 2Service d’hépato-gastroentérologie et d’oncologie digestive, Groupe Hospitalier Saint André, Bordeaux, France; 3Service d'Hépato-Gastro-Entérologie, Hôpital de la Croix Rousse, Lyon, France; 4Dipartimento di Oncologia Medica, Ospedale San Raffaele IRCSS, Milan, Italy; 5Servizio di Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy; 6Service Hépatologie, Hôpital Jean-Verdier, Bondy, France; 7Service d'hepato-gastro-enterologie, CHU de Grenoble - Hôpital Nord, Grenoble, France; 8Gastrointestinal Oncology, Goethe University Hospital, Frankfurt, Germany; 9Policlinico di Modena, Modena, Italy; 10Merck KGaA, Darmstadt, Germany
Welcome to watch Creative Biolabs’ slide about immune system and immune therapy. here we share some basic knowledge about T Cell Receptor Engineered T Cell Technology or TCR-T and its application on tumor therapy.
This slides briefly introduced why car t cell validation assay is essential for car t therapy development and which assays should be done to validate the safety, identity, purity and potency of car t cell products.
This document discusses the diagnosis and genetic testing of primary immunodeficiencies. It begins by defining primary immunodeficiency as congenital or hereditary defects of the immune system resulting in increased infections. It then classifies primary immunodeficiencies and lists the most common infectious agents seen. The document goes on to discuss specific genetic mutations that can cause various forms of severe combined immunodeficiency (SCID) or other primary immunodeficiencies. Case studies are presented to illustrate the genetic testing process and diagnosis of conditions like perforin deficiency.
This paper reports phase II clinical data on galunisertib, a novel small molecule TGF-beta receptor inhibitor in patients with advanced non-operable hepatocellular carcinoma. This poster was presented at ASCO 2016 in Chicago. Results show activity and mild toxicity.
Rapid diagnostic tests (RDTs) are useful for the rapid diagnosis of malaria. A study compared RDTs to microscopic examination in 43 malaria cases. RDTs diagnosed 41 cases (96%), while microscopy diagnosed 34 cases. Most cases were Plasmodium falciparum (88%). RDTs had high sensitivity (96.5%) but low specificity (21.4%) for P. falciparum. It was more effective at diagnosing malaria than microscopy. The study concluded that RDTs provide a simple, rapid and accurate method for malaria diagnosis, especially in remote areas where microscopy is not available.
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Andrew Aijian
Analysis and synthesis of a pulse survey conducted across >140 oncologists, pathologists, and lab directors regarding current adoption and trends associated with emerging oncology biomarkers and companion diagnostics (CDx), with an emphasis on next-generation sequencing (NGS)-based CDx.
ỨNG DỤNG CHẨN ĐOÁN PHÂN TỬ TRONG NHÓM BỆNH UNG THƯ nataliej4
Molecular diagnostic tests play an important role in the management of non-small cell lung cancer (NSCLC). Mutations in the epidermal growth factor receptor (EGFR) gene are commonly detected in NSCLC, especially in Asian populations, and help guide targeted therapy decisions. The cobas® EGFR Mutation Test is an FDA-approved real-time PCR test that detects 42 mutations in EGFR exons 18, 19, 20 and 21 in tissue and plasma samples. It provides a semi-quantitative index to monitor changes in mutant circulating tumor DNA levels over time, aiding in NSCLC patient management. EGFR mutation testing is crucial for identifying patients eligible for EGFR tyrosine kinase inhibitors.
This document summarizes a presentation on new targets and agents for hepatocellular carcinoma. It discusses several new targets including VEGFR, PDGFR, c-MET, FGFR4, TGF-β, and PD-1/PDL1 that are being investigated with new agents. Regorafenib and nivolumab are highlighted as agents that have shown survival benefits in late stage trials for HCC. Other agents discussed include tepotinib as a c-MET inhibitor and galunisertib as a TGF-β inhibitor. Combination approaches are also a focus, including using PD-L1 inhibitors with other agents and combining galunisertib with sorafenib.
HDx™ Reference Standards and Reference Materials for Next Generation Sequenci...Candy Smellie
This document summarizes a presentation about reference standards for next generation sequencing (NGS). Horizon Diagnostics has developed genomic DNA and formalin-fixed, paraffin-embedded (FFPE) reference standards containing defined mutations at known allelic frequencies to validate NGS workflows and monitor assay performance. Multiplex reference standards contain up to 40 mutations at low allelic frequencies down to 1.3% that can be quantified using digital PCR. Several laboratories demonstrated they could accurately detect the mutations in Horizon's reference standards using different NGS platforms. The standards help evaluate sensitivity, specificity, and limits of detection on NGS assays.
This PPT is about immune system and immune therapy, some basic knowledge about Chimeric Antigen Receptor or CAR technology and its application on tumor therapy.
“Regulatory experience with monoclonal antibody submissions in the EU”
Provides an overview of the current EU assessment of biotherapeutics, focusing specifically on monoclonal antibodies
Greece Orthopedic Devices Investment Opportunities, Analysis and Forecasts to...ReportsnReports
The document provides a summary of a 250-page report on investment opportunities in the orthopedic devices market in Greece from 2012 to 2018. It analyzes the market size, trends, forecasts, and company shares for various orthopedic device categories. Key data and analysis are provided for 12 orthopedic device market segments, including revenue and volume forecasts from 2004 to 2018 with 2011 company share data. The report aims to help readers develop business strategies for strong growth areas and identify competitive landscapes in the Greece orthopedic devices market.
Biopharmaceuticals are large molecule drugs made using cells or enzymes, often similar to natural biological compounds. Examples include proteins, peptides, nucleic acids, and gene therapy. The first approved biopharmaceuticals were recombinant human insulin in 1982 and recombinant tissue plasminogen activator in 1986. Today, biopharmaceutical sales reach over $200 billion annually and there are over 300 approved biopharmaceutical drugs on the market. Biopharmaceuticals are mainly produced using bacterial, mammalian, yeast, plant, or animal cells transfected with plasmids containing the gene for the target protein. Purification then isolates the target protein for clinical use.
Dr. maryalice stetler stevenson lymphoma mrdHitham Esam
Flow cytometry can be used to detect minimal residual disease (MRD) in plasma cell neoplasms such as multiple myeloma. It provides both prognostic information and a way to measure response to drug therapies. Several factors are important for obtaining high quality flow cytometry results, including using bone marrow aspirates within 24 hours of collection, lysing red blood cells, acquiring sufficient events, and using standardized staining and gating strategies. Detection of MRD by flow post-treatment is predictive of patient outcomes and can guide clinical decision making.
This document provides an overview of AV Therapeutics, a biotechnology company developing safer and more effective chemotherapeutic agents. Their lead drug candidate, Capridine-β, shows promise for treating prostate cancer. It has demonstrated efficacy against hormone-responsive and non-responsive prostate cancer xenografts in mice, with limited side effects. Capridine-β is a patented anticancer drug that kills prostate cancer cells preferentially over other cell types and has been shown to be more potent than other drugs like taxanes. AV Therapeutics aims to develop Capridine-β as an effective drug-based therapy for prostate cancer with a better safety profile than existing options.
"Familial" versus "sporadic" Intellectual Disability: Contribution of DNA Cop...Maryam Rafati
This document appears to be a PhD thesis presentation by Maryam Rafati at Tehran University of Medical Sciences on February 15, 2012. The presentation aims to determine the genetic causes of familial mental retardation (MR) and whether a different diagnostic approach should be used for familial versus sporadic MR cases. It involves studying 426 sporadic and familial MR patients using techniques such as karyotyping, fragile X testing, subtelomeric and microdeletion/duplication analysis, and array comparative genomic hybridization. The results identified chromosomal abnormalities, syndromes and single gene disorders in 41 patients, demonstrating the utility of genetic testing in familial MR cases.
GPCR ligand screening assay
Monitors the very early activation stage of Frizzled-Receptors of the GPCR group
Our assay can be implemented in a cell-free chemical compound high-throughput target screening. GPCR is the largest known category of molecular targets with verified therapeutic value. Up to 40% of approved drugs are targeted to GPCRs. 25% of the top 200 best-selling drug targets are GPCRs.
Dr. maryalice stetler stevenson b-all mrdHitham Esam
Flow cytometry plays an important role in detecting minimal residual disease (MRD) in B-cell acute lymphoblastic leukemia (B-ALL). Studies by the Children's Oncology Group (COG) determined that a level of >0.01% MRD detected by flow cytometry indicates higher risk and is clinically relevant. The COG assay uses specific antibody panels to identify and quantify residual leukemia blasts in bone marrow samples. The assay was validated across laboratories, showing the same results and prognostic value. Standardized gating strategies and analytical techniques are crucial for accurate and reproducible MRD detection by flow cytometry.
The document evaluates the usefulness of rapid diagnostic tests (RDTs) for diagnosing malaria compared to microscopic examination. It finds that RDTs diagnosed 41 out of 43 total malaria cases in the study, while microscopy only diagnosed 34 cases. RDTs were found to be highly sensitive (96.55%) and specific (71.79%) for detecting Plasmodium falciparum malaria compared to microscopy. The study concludes that RDTs are an effective, rapid and accurate method for diagnosing malaria, especially in cases where immediate diagnosis is needed. RDTs performed better than microscopy and using both tests together provides the best approach for malaria diagnosis.
Poster presentation at the 2016 WORLD GASTROINTESTINAL SYMPOSIUM on tepotinib a selective inhibitor of c-MET by S. Faivre, J.-F. Blanc, P. Merle, A. Fasolo, A. Iacobellis, V. Grando, T. Decaens, J. Trojan, E. Villa, U. Stammberger, R. Bruns, E. Raymond
1Oncology Unit, Beaujon University Hospital, Clichy, France; 2Service d’hépato-gastroentérologie et d’oncologie digestive, Groupe Hospitalier Saint André, Bordeaux, France; 3Service d'Hépato-Gastro-Entérologie, Hôpital de la Croix Rousse, Lyon, France; 4Dipartimento di Oncologia Medica, Ospedale San Raffaele IRCSS, Milan, Italy; 5Servizio di Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy; 6Service Hépatologie, Hôpital Jean-Verdier, Bondy, France; 7Service d'hepato-gastro-enterologie, CHU de Grenoble - Hôpital Nord, Grenoble, France; 8Gastrointestinal Oncology, Goethe University Hospital, Frankfurt, Germany; 9Policlinico di Modena, Modena, Italy; 10Merck KGaA, Darmstadt, Germany
Welcome to watch Creative Biolabs’ slide about immune system and immune therapy. here we share some basic knowledge about T Cell Receptor Engineered T Cell Technology or TCR-T and its application on tumor therapy.
This slides briefly introduced why car t cell validation assay is essential for car t therapy development and which assays should be done to validate the safety, identity, purity and potency of car t cell products.
This document discusses the diagnosis and genetic testing of primary immunodeficiencies. It begins by defining primary immunodeficiency as congenital or hereditary defects of the immune system resulting in increased infections. It then classifies primary immunodeficiencies and lists the most common infectious agents seen. The document goes on to discuss specific genetic mutations that can cause various forms of severe combined immunodeficiency (SCID) or other primary immunodeficiencies. Case studies are presented to illustrate the genetic testing process and diagnosis of conditions like perforin deficiency.
This paper reports phase II clinical data on galunisertib, a novel small molecule TGF-beta receptor inhibitor in patients with advanced non-operable hepatocellular carcinoma. This poster was presented at ASCO 2016 in Chicago. Results show activity and mild toxicity.
Rapid diagnostic tests (RDTs) are useful for the rapid diagnosis of malaria. A study compared RDTs to microscopic examination in 43 malaria cases. RDTs diagnosed 41 cases (96%), while microscopy diagnosed 34 cases. Most cases were Plasmodium falciparum (88%). RDTs had high sensitivity (96.5%) but low specificity (21.4%) for P. falciparum. It was more effective at diagnosing malaria than microscopy. The study concluded that RDTs provide a simple, rapid and accurate method for malaria diagnosis, especially in remote areas where microscopy is not available.
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Andrew Aijian
Analysis and synthesis of a pulse survey conducted across >140 oncologists, pathologists, and lab directors regarding current adoption and trends associated with emerging oncology biomarkers and companion diagnostics (CDx), with an emphasis on next-generation sequencing (NGS)-based CDx.
ỨNG DỤNG CHẨN ĐOÁN PHÂN TỬ TRONG NHÓM BỆNH UNG THƯ nataliej4
Molecular diagnostic tests play an important role in the management of non-small cell lung cancer (NSCLC). Mutations in the epidermal growth factor receptor (EGFR) gene are commonly detected in NSCLC, especially in Asian populations, and help guide targeted therapy decisions. The cobas® EGFR Mutation Test is an FDA-approved real-time PCR test that detects 42 mutations in EGFR exons 18, 19, 20 and 21 in tissue and plasma samples. It provides a semi-quantitative index to monitor changes in mutant circulating tumor DNA levels over time, aiding in NSCLC patient management. EGFR mutation testing is crucial for identifying patients eligible for EGFR tyrosine kinase inhibitors.
This document summarizes a presentation on new targets and agents for hepatocellular carcinoma. It discusses several new targets including VEGFR, PDGFR, c-MET, FGFR4, TGF-β, and PD-1/PDL1 that are being investigated with new agents. Regorafenib and nivolumab are highlighted as agents that have shown survival benefits in late stage trials for HCC. Other agents discussed include tepotinib as a c-MET inhibitor and galunisertib as a TGF-β inhibitor. Combination approaches are also a focus, including using PD-L1 inhibitors with other agents and combining galunisertib with sorafenib.
HDx™ Reference Standards and Reference Materials for Next Generation Sequenci...Candy Smellie
This document summarizes a presentation about reference standards for next generation sequencing (NGS). Horizon Diagnostics has developed genomic DNA and formalin-fixed, paraffin-embedded (FFPE) reference standards containing defined mutations at known allelic frequencies to validate NGS workflows and monitor assay performance. Multiplex reference standards contain up to 40 mutations at low allelic frequencies down to 1.3% that can be quantified using digital PCR. Several laboratories demonstrated they could accurately detect the mutations in Horizon's reference standards using different NGS platforms. The standards help evaluate sensitivity, specificity, and limits of detection on NGS assays.
This PPT is about immune system and immune therapy, some basic knowledge about Chimeric Antigen Receptor or CAR technology and its application on tumor therapy.
“Regulatory experience with monoclonal antibody submissions in the EU”
Provides an overview of the current EU assessment of biotherapeutics, focusing specifically on monoclonal antibodies
Greece Orthopedic Devices Investment Opportunities, Analysis and Forecasts to...ReportsnReports
The document provides a summary of a 250-page report on investment opportunities in the orthopedic devices market in Greece from 2012 to 2018. It analyzes the market size, trends, forecasts, and company shares for various orthopedic device categories. Key data and analysis are provided for 12 orthopedic device market segments, including revenue and volume forecasts from 2004 to 2018 with 2011 company share data. The report aims to help readers develop business strategies for strong growth areas and identify competitive landscapes in the Greece orthopedic devices market.
Facebook 101, Marketing Leadership, and the Evolving Age of New MediaBenjamin Kirby
The document provides an overview of Facebook, including its launch in 2004 as a social networking site, current statistics on its user base of over 845 million monthly active users, and how it has evolved through acquiring companies like Instagram and integrating technologies like mobile. It discusses Facebook's goal of becoming a unified platform for communications and content across different devices. The document also provides guidance for non-profit organizations on using Facebook for branding, engagement, and analytics.
Denmark Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Manage...ReportsnReports
This report provides an in-depth analysis of the cardiovascular devices market in Denmark from 2004-2018. It covers 10 device categories and provides revenue, volume, and price data for each segment. The 408-page report was published in September 2012 and costs $2,500 for a single-user license. It uses proprietary data and primary/secondary research to analyze market size, company shares, distribution shares, and profiles of key companies in the Danish cardiovascular devices market.
Germany Diagnostic Imaging Market Outlook to 2018 - Ultrasound Systems, MRI S...ReportsnReports
This report provides an in-depth analysis of the diagnostic imaging market in Germany from 2004-2018. It covers market revenue, volume, and price trends for 10 categories: Angio Suites, Bone Densitometers, C-Arms, Computed Tomography Systems, Contrast Media Injectors, Mammography Equipment, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems, and X-Ray Systems. It also provides company market shares for major players like Siemens Healthcare, GE Healthcare, and Philips Healthcare. The 237-page report is available for purchase for $2,500 and contains detailed historical data and forecasts, as well as profiles of key market participants.
ERP for Construction Industry and Infrastructure. Eresource ERP for Construction is a comprehensive ERP solution designed by taking utmost care with core functionality of the industry in mind
This 90-page report examines emerging superfruits in the global food and drinks market using data on product launches, patents, health claims, and clinical trials. Blueberry and pomegranate are currently the most popular superfruits, but chokeberry, jujube, and seabuckthorn are gaining ground. The report identifies these up-and-coming superfruits and analyzes trends in new products, patents, health claims, and clinical trials to determine future opportunities for food and drink companies in the superfruit space.
Tablet Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018ReportsnReports
The document provides an in-depth analysis of the global tablet market from 2012 to 2018, including market shares, strategies, and forecasts. It details quarterly and annual shipment numbers for major tablet manufacturers like Apple, Samsung, and Amazon. The 334-page report also examines the competitive tablet landscape, emerging features, operating systems, pricing trends, and regional shipment analyses. Key factors influencing the market are discussed, such as usability, bring-your-own-device policies, and the integration of hardware, software, and services across platforms. Worldwide tablet revenues are projected to grow from $32 billion in 2011 to $181.5 billion by 2018.
The document presents two solutions for secure internet banking authentication - one based on short-time passwords using hardware security modules, and the other based on certificate-based authentication using smart cards. It discusses current authentication threats like offline credential stealing and online channel breaking attacks. Both proposed solutions offer strong security against these common attacks, with the certificate-based solution being highly attractive for the future due to changing legislation and the spread of electronic IDs.
This document discusses using Xtranormal videos to enhance hybrid and online courses. It provides an introduction to the speaker and outlines four workshop objectives, including explaining and demonstrating Xtranormal videos. Three potential uses for Xtranormal videos in education are described: teaching concepts, providing staff training case studies, and student-created videos. Details are given on how to make Xtranormal videos, and participants are invited to start writing a script.
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...ReportsnReports
This document provides a 1050-page report on the global molecular diagnostics market, published in December 2012. It explores business and technology trends in major markets, provides test volume/sales forecasts, compares diagnostic platforms, and identifies opportunities for instrument and reagent suppliers through 2022. The molecular diagnostics market is growing rapidly as new automated systems and cost-effective products are introduced. Companies must integrate new technology and business strategies to capitalize on emerging opportunities in this field over the next decade.
Germany Molecular Diagnostics Market: Innovative Technologies and Emerging Bu...ReportsnReports
This 850-page report provides a comprehensive analysis of the German molecular diagnostics market, including major issues, trends, technologies, test categories, suppliers, and business opportunities. It forecasts test volumes and reagent sales for infectious diseases, genetic diseases, cancer, and other applications over 10 years. The report profiles leading suppliers and identifies over 60 specific product opportunities. It also discusses alternative market entry strategies and potential barriers.
2013 US Tumor Marker Testing Market: Opportunities and Strategies for SupplierReportsnReports
This 620-page report provides a comprehensive analysis of the US tumor marker testing market, including cancer statistics, current and emerging diagnostic tests, instrumentation technologies, test volume and sales forecasts through 2023 for various market segments. It highlights major opportunities for suppliers in reagent kits, instrumentation, automation, and software. The report profiles current and emerging suppliers and provides strategic recommendations to support business strategies.
Future Horizons in the UK Cancer Diagnostics Market: Supplier Shares and Sale...ReportsnReports
This 575-page report provides a comprehensive analysis of the UK tumor marker testing market, including 10-year test volume and sales forecasts for 40 tumor markers across hospital, commercial, and physician office market segments. It highlights key issues in UK laboratory practice and analyzes the impact of economic, regulatory, demographic, social, and technological trends. The report also profiles current and emerging suppliers and provides strategic recommendations.
Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares an...ReportsnReports
This document provides a 590-page report on the Japanese cancer diagnostics market, including test volume and sales forecasts through 2022 for 40 tumor markers across hospital, commercial, and physician office settings. It highlights key issues in the Japanese laboratory practice and analyzes economic, regulatory, demographic, and technological trends impacting the market. The report also profiles major suppliers and provides strategic recommendations.
US Microbiology Testing Market: Innovative Technologies and Emerging Business...ReportsnReports
The document provides a 1037-page analysis of the US microbiology testing market, including forecasts for test volumes and sales of 80 microbiology tests performed in hospitals, blood banks, and commercial/private labs over the next 10 years. It also discusses emerging diagnostic technologies, profiles current and emerging suppliers, and identifies business opportunities in the market. The table of contents outlines topics like major infectious diseases and diagnostic tests, instrumentation technologies, emerging technologies, the US market structure and size, and product development opportunities.
UK Microbiology Testing Market: Innovative Technologies and Emerging Business...ReportsnReports
This 978-page report provides a comprehensive analysis of the UK microbiology testing market, including major infectious disease tests, emerging diagnostic technologies, test volume and sales forecasts, supplier market shares, and business opportunities. The report covers nearly 80 microbiology tests and profiles current and emerging suppliers, outlining their product portfolios, marketing strategies, and business development activities. It is available for purchase at US$5900 for a single-user license.
Future Horizons in the UK Infectious Disease Testing Market: Supplier Shares ...ReportsnReports
The document provides a 978-page analysis of the UK infectious disease testing market over the next ten years. It includes test volume and sales forecasts for nearly 80 microbiology tests across various market segments in the UK. It also profiles current and emerging suppliers and provides strategic recommendations. The document covers major issues related to UK microbiology laboratory practice and key trends impacting the market.
Future Horizons in the Japanese Infectious Disease Testing Market: Supplier S...ReportsnReports
This document provides a 976-page analysis of the Japanese microbiology testing market over the next 10 years. It includes forecasts for test volumes and sales for nearly 80 microbiology tests across hospital, blood bank, and commercial laboratories in Japan. It also discusses the leading suppliers in the market, emerging diagnostic technologies, and business opportunities.
Spain Microbiology Testing Market: Innovative Technologies and Emerging Busin...ReportsnReports
This document provides a 960-page analysis of the Spanish microbiology testing market. It includes forecasts for 80 microbiology tests over 10 years, profiles of suppliers, emerging technologies, and business opportunities. Major sections cover infectious disease tests, instrumentation, the Spanish business environment, and competitive assessments of leading suppliers.
Spain Microbiology Testing Market: Innovative Technologies and Emerging Busin...ReportsnReports
This document provides a 960-page analysis of the Spanish microbiology testing market. It includes forecasts for test volumes and sales of 80 microbiology tests performed in Spanish hospitals, blood banks, and commercial labs over the next 10 years. It also discusses emerging diagnostic technologies, business opportunities, and profiles of suppliers in the Spanish market. The document aims to provide a comprehensive overview of the current and future state of the Spanish microbiology testing industry.
Future Horizons in the European Cancer Diagnostics Market - France, Germany, ...ReportsnReports
This report provides a comprehensive analysis of the cancer diagnostics market in five European countries from 2012-2017. It examines trends, reviews current and emerging tests, forecasts sales of 40 tumor markers by country, and profiles leading market players. The market is poised for rapid expansion as technological breakthroughs create new opportunities in genetic testing, tumor detection, and cancer therapy monitoring. An aging population will further increase demand for diagnostic assays and tests. The report is based on 820 pages of analysis and is available for individual purchase at $18,500.
Japan Microbiology Testing Market: Innovative Technologies and Emerging Busin...ReportsnReports
This document provides a 970-page analysis of the Japan microbiology testing market, including forecasts for test volumes and sales for various infectious diseases over 10 years. It covers major technologies, suppliers, business opportunities, and strategic recommendations. The table of contents indicates it discusses individual disease tests, instrumentation, emerging technologies, the business environment in Japan, and competitive assessments of major suppliers.
Germany Microbiology Testing Market: Innovative Technologies and Emerging Bus...ReportsnReports
This document provides a 983-page analysis of the German microbiology testing market. It includes forecasts for test volumes and sales for 80 microbiology tests performed in German hospitals, blood banks, and commercial labs over the next 10 years. It also discusses emerging diagnostic technologies, product development opportunities, and competitive profiles of suppliers in the German market. The table of contents outlines the extensive coverage of major infectious diseases and diagnostic tests.
Analysis of Emerging Molecular Diagnostics Tests And Strategic Profiles of Le...ReportsnReports
This 505-page report analyzes emerging molecular diagnostic tests and profiles leading suppliers in the field. It provides an overview of clinical significance and market needs for major current and emerging tests in areas like infectious diseases, cancer, and genetic testing. The report is available for $4,750 and contains extensive company profiles of organizations developing molecular diagnostic technologies and products.
Italian Microbiology Testing Market: Innovative Technologies and Emerging Bus...ReportsnReports
This document provides a 970-page analysis of the Italian microbiology testing market, including forecasts for test volumes and sales for 80 microbiology tests over the next 10 years. It covers major infectious diseases and microorganisms, emerging diagnostic technologies, profiles of suppliers, and business opportunities in the Italian market. The table of contents shows that it examines issues related to individual infectious agents and provides an extensive review of leading diagnostic instrumentation and technologies.
Italian Microbiology Testing Market: Innovative Technologies and Emerging Bus...ReportsnReports
This document provides a 970-page analysis of the Italian microbiology testing market, including forecasts for test volumes and sales for 80 microbiology tests over the next 10 years. It covers major infectious diseases and microorganisms, emerging diagnostic technologies, profiles of suppliers, and business opportunities in the Italian market. The table of contents shows that it examines issues related to individual infectious agents and provides an extensive review of leading diagnostic instrumentation and technologies.
Italian Microbiology Testing Market: Innovative Technologies and Emerging Bus...ReportsnReports
This document provides a 970-page analysis of the Italian microbiology testing market, including forecasts for test volumes and sales for 80 microbiology tests over the next 10 years. It covers major infectious diseases and microorganisms, emerging diagnostic technologies, profiles of suppliers, and business opportunities in the Italian market. The table of contents shows that it examines issues related to individual infectious agents and provides an extensive review of leading diagnostic instrumentation and technologies.
Innovative Cancer Diagnostic Technologies and Emerging MarketsReportsnReports
This document provides a 1200-page report on innovative cancer diagnostic technologies and emerging markets published in November 2012. It identifies business opportunities in the cancer diagnostics market over the next ten years in 7 countries. The report examines trends, reviews current and emerging tests, forecasts sales of tumor markers by country/market, and profiles leading and potential market players. It also evaluates major diagnostic instruments and suggests strategies for suppliers.
2013 Japanese Microbiology Testing Market: Opportunities and Strategies for S...ReportsnReports
This document provides a 976-page report on the 2013 Japanese microbiology testing market, opportunities, and strategies for suppliers. It highlights major issues in Japanese microbiology practice and economic/regulatory trends impacting the market. It provides 10-year test volume and sales forecasts for 80 microbiology tests in Japanese hospitals, blood banks, and commercial labs. It also reviews instrumentation technologies, emerging diagnostic technologies, product development opportunities, and profiles of current and emerging suppliers. The table of contents outlines the extensive coverage of individual infectious diseases and diagnostic tests.
Similar to France Molecular Diagnostics Market: Innovative Technologies and Emerging Business Opportunities (20)
2013 Japanese Microbiology Testing Market: Opportunities and Strategies for S...
France Molecular Diagnostics Market: Innovative Technologies and Emerging Business Opportunities
1. France Molecular Diagnostics Market: Innovative Technologies
and Emerging Business Opportunities
Report Details:
Published:December 2012
No. of Pages: 850
Price: Single User License – US$5900
This report presents a comprehensive analysis of the French molecular diagnostics market,
including:
•Major issues pertaining to the French molecular diagnostics laboratory practice, as well as key
economic, regulatory, demographic, social and technological trends with significant market impact
during the next ten years.
•An extensive review of DNA probe and biochip technologies, test formats, detection
methodologies, trends in testing automation and amplification methods.
•Ten-year test volume and reagent sales forecasts for the following categories:
•Infectious Diseases
•Genetic Diseases
•Cancer
•Paternity Testing/HLA Typing
•Forensic Testing
• Review of testing methodologies an instrumentation technologies.
•Feature comparison of automated and semiautomated analyzers.
•Sales and market shares of leading suppliers.
•Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary
products.
•Profiles of major suppliers, and emerging market entrants, including their sales, product
portfolios, marketing tactics, technological know-how, new products in R&D, collaborative
arrangements and business strategies.
•Alternative market penetration strategies.
•Potential market entry barriers and risks.
•Business planning issues and concerns.
Get your copy of this report @
http://www.reportsnreports.com/reports/210782-france-molecular-diagnostics-market-innovative-technologies-and-
emerging-business-opportunities.html
2. Major points covered in Table of Contents of this report include
Table of Contents
Introduction
Worldwide Market And Technology Overview
A. DNA Sequencing
1. Introduction
2. Sequencing Methods
3. Autoradiography
4. The Human Genome Project
5. Sequencing Automation
6. Image Scanners
7. Fluorescent Detection
8. Gene Profiling
9. Gene Expression
10. Polymorphism Screening
11. Protein Interaction Networks
B. DNA And RNA Probe Technology
1. Basic Principles
2. Probe Preparation
3. The DNA Probe Test
a. Sample Preparation
b. Hybridization
c. Separation
d. Detection/Measurement
4. Test Formats
a. Filter Hybridization
b. Southern Blot
c. Northern Blot
d. In Situ Hybridization
e. Others
5. Labeling Techniques
6. Amplification Methods
Polymerase Chain Reaction
Temperature Cyclers
PCR Variations
Immuno-PCR
QC-PCR
DAP-PCR
Strand Displacement Activation
TMA
Ligase Chain Reaction
Branched DNA
3. Hybridization Protection Assay
Nucleic-Acid Sequence-Based Amplification
Self-Sustained Sequence Replicase
Others
Ampliprobe
CAR
CAS
CPT
Dendritic Polymer Technology
ISO-CR
LAT
Probe Networks
RAMP
Repair Chain Reaction
Rolling Circles
Sequence Independent Gene Amplification
Sequence Initiation Reaction
SISPA
Solid Phase Amplification
C. Detection Technologies
1. Radioactive Methods
a. Overview
b. Major Isotopes
P-32
S-35
H-3
I-125
2. Non-Isotopic Methods
a. Enzymatic Labels
b. Chemical Labeling
Indirect Chemical Labeling
Direct Chemical Labeling
c. Fluorescence
d. Chemiluminescence
e. Electrical Conductivity
D. Instrumentation Review
1. Abbott LCx
2. Beckman Coulter/Biomek FK
3. Becton Dickinson SDA
4. Bio-Rad GeneScope
5. Gen-Probe Tigris
6. Roche Cobas Amplicor
4. 7. Tecan LS Series
E. Biochips: Genosensors, Microarrays, and Labs-on-the-Chip
Liquid Transportation and Mixing
Separation
Reaction
Detection
F. Pharmacogenomics
G. Major Applications
1. Microbiology/Infectious Diseases
a. Overview
b. Major Infectious Diseases
AIDS
Structure and Composition
Classification
AIDS Origins
Animal Lentivirus Systems
Virus Receptors
HIV Infections in Humans
Pathogenesis and Pathology
CD4T Lymphocytes and Memory Cells
Monocytes and Macrophages
Lymphoid Organs
Neural Cells
Viral Coinfections
Clinical Findings
Plasma Viral Load
Pediatric AIDS
Neurologic Disease
Opportunistic Infections
Cancer
Immunity
Virus Isolation
Serology
Viral Nucleic Acid/Antigen Detection
Epidemiology
Worldwide Spread of AIDS
United States
Routes of Transmission
DNA Probes
Overview
Quantitative PCR
In Situ PCR
5. Needed Improvements
Viral Load/Drug Resistance Testing
Genotype and Phenotype Testing
Blood Banking Considerations
Adenovirus
Background
Diagnostic Tests
Vaccines and Drugs
Adeno-Associated Viruses (AAV)
Anthrax/Bacillus Anthracis
Background
Diagnostic Tests
Vaccines and Drugs
Babesiosis
Background
BEA and Other Bartonella Diseases
Background
Diagnostic Tests
Vaccines and Drugs
Chagas Disease
Background
Campylobacter
Background
Diagnostic Tests
Culture Identification
Vaccines and Drugs
Chlamydia
Background
Chlamydia psittaci
Chlmaydia pneumoniae
Chlamydia trachomatis
Diagnostic Tests
Vaccines and Drugs
Creutzfeldt-Jakob’s Disease
Background
Blood Transmission
Diagnostic Tests
Major Commercial and Academic Players
Bayer
Disease Sciences/Bio Tec Global
Imperial College School of Medicine
Ortho-Clinical Diagnostics
6. Pall
ProMetic Life Sciences
Proteome Sciences/Idexx
Q-One Biotech
Serono
U.S. Agricultural Research Service
Drugs
Vaccines
Cytomegalovirus
Background
Chorioretinitis
Gastrointestinal
Central Nervous System Disease
Diagnostic Tests
Vaccines and Drugs
Ebola Virus
Background
Epidemiology
Clinical Syndromes
Diagnostic Tests
Vaccines and Drugs
EchoVirus
Background
Acute Aseptic Meningitisis
Encephalitis
Exanthems
Respiratory Disease
Myopericarditis
Neonatal Infections
Diagnostic Tests
Vaccines and Drugs
Encephalitis
Background
Diagnostic Tests
Vaccines and Drugs
Enteroviruses
Background
Diagnostic Tests
Viral Isolation and Identification
Antibody Tests
Vaccines and Drugs
Epstein-Barr Virus
7. Background
Diagnostic Tests
Vaccines and Drugs
Gonorrhea
Background
Diagnostic Tests
Vaccines and Drugs
Hepatitis
Hepatitis A
Hepatitis B
Structure and Composition
Replication
Hepatitis C
Hepatitis D (Delta)
Hepatitis E
Hepatitis G
Hepatitis Infections Pathology
Clinical Findings
Laboratory Tests
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatitis E
Virus-Host Immune Reactions
Epidemiology
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D (Delta)
Vaccines and Drugs
Herpes Simplex Virus
Background
Diagnostic Tests
Vaccines and Drugs
Legionella
Background
Diagnostic Tests
Vaccines and Drugs
Lyme Disease
Background
Clinical Description
8. Clinical Case Definition
Laboratory Criteria for Diagnosis
Case Classification
Diagnostic Tests
Vaccines and Drugs
Malaria
Mycoplasma
Background
Ureaplasma Urealyticum & Mycoplasma
Hominis
Diagnostic Tests
Vaccines and Drugs
Papillomaviruses/HPV
Background
HPV in Cancer
Cervical Neoplasm
Diagnostic Tests
Vaccines and Drugs
Prevention
Parvovirus B19
Background
Microbiology
Epidemiology
Clinical Syndromes
Erythema Infectiosum (Slapped Cheek)
Adult Polyarthropathy
Transient Aplastic Crisis
Transient Pancytopenia
Red Cell Aplasia in Immunocompromised
Perinatal Infections
Diagnostic Test
Vaccines and Drugs
Pneumonia
Background
Diagnostic Tests
Vaccines and Drugs
Polyomaviruses
Background
Diagnostic Tests
Vaccines and Drugs
Salmonellosis
Background
9. Diagnostic Tests
Vaccines and Drugs
Shigellosis
Background
Diagnostic Tests
Vaccines and Drugs
Streptococci
Background
Diagnostic Tests
Vaccines and Drugs
Group A Streptococci
Group B Streptococci
Toxoplasmosis
Background
Diagnostic Tests
Vaccines and Drugs
Tuberculosis
Background
Diagnostic Tests
Microscopic Characteristics
Cultural Characteristics
Skin Tests
MDRTB
Vaccines and Drugs
West Nile Virus
Background
Clinical Syndromes
Diagnostic Tests
Vaccines and Drugs
Yersinia
Background
Diagnostic Tests
Vaccines and Drugs
c. Antibiotic Susceptibility
2. Cancer Testing
a. Overview
b. Major Cancer Types
Prostate
Lung
Colon and Rectum
Breast
Skin
11. Factor V (Leiden)
Factor IX Deficiency
Fragile X Syndrome
Heart Disease
Hemochomatosis
Hemophilia
Huntington's Disease
Maternal-Fetal Incompatibility
Multiple Endocrine Neoplasia
Phenylketonuria (PKU)
Polycystic Kidney Disease (PKD)
Prenatal Screening
Retinitis Pigmentosa
Retinoblastoma
Sickle Cell Anemia
Spinal Muscular Atrophy
Vitamin B12 Metabolism
i. Social Issues and Concerns
4. Forensic Testing
a. Overview
b. Multilocus and Single Locus Probes
Multilocus Probes
Single Locus Probes
PCR and RFLP
c. The FBI
d. DNA Profile Data Banks
U.S.A.
U.K.
e. Judicial Implementation
f. Major Crime Categories
g. Factors Contributing to the DNA Probe
Market Expansion
Technology Availability
Use of Hair as Evidence
h. Wildlife Forensics
5. Paternity Testing/HLA Typing
6. Other Applications
a. Disease Susceptibility Testing
b. Cardiovascular Diseases
c. Diabetes
d. Alzheimer's Disease
e. Periodontal Disease
12. f. Plasma Purification
g. Organ Transplantation
h. Water Contamination
i. Other
H. Competing/complementing Technologies
1. Monoclonal Antibodies/Immunoassays
2. RNA Probes
3. Two-Dimensional Electrophoresis
4. Flow Cytometry
Table of Contents (continued)
France
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth And Major Suppliers’
Sales And Market Shares
Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products
Design Criteria For Decentralized Testing Products
Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies For Decentralized Testing Markets
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types Of Distributors
7. Market Segmentation
Potential Market Entry Barriers And Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge And Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
14. Tecan Group
Appendix I: Major Universities and Research Centers
Developing Molecular Diagnostic Technology
Appendix II: Glossary of Terms
Appendix III: Currency Exchange Rates
List of Tables
Major Companies Developing or Marketing AIDS Molecular
Diagnostic And Other Direct Identification Tests
Major Companies Developing or Marketing Adenovirus
Molecular Diagnostic And Other Direct Identification Tests
Major Companies Developing or Marketing Campylobacter
Molecular Diagnostic And Other Direct Identification Tests
Major Companies Developing or Marketing Chlamydia Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing CMV Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing EBV Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Gonorrhea Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Hepatitis Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Herpes Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Legionella Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Lyme Disease Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Mycoplasma Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Papilloma Virus Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Pneumonia Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Salmonella Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Shigella Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Streptococci Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Toxoplasmosis Molecular Diagnostic And Other Direct
Identification Tests
15. Major Companies Developing or Marketing Tuberculosis Molecular Diagnostic And Other Direct
Identification Tests
Oncogenes Potential Application in Cancer Diagnosis
Major Companies Developing or Marketing Cancer Molecular Diagnostic Tests
Major Companies Developing or Marketing Molecular Diagnostic Test For Genetic Diseases
Summary Table France, Molecular Diagnostic Test Volume And Sales Forecast by Major
Application
France, Laboratories Performing DNA Sequencing By Market Segment
France, Molecular Diagnostics Market Potential Laboratory Universe by Market Segment
France, Molecular Diagnostic Test Volume Forecast By Major Application
France, Major Infectious Disease Molecular Diagnostics Test Volume Forecast
France, Infectious Disease Screening NAT Volume Forecast
France, Molecular Diagnostics Market Forecast By Major Application
France, Infectious Disease Screening NAT Reagent Market Forecast by Test
France, Molecular Diagnostics Market By Major Supplier
France, HIV/Hepatitis NAT Market Reagent Sales By Major Supplier
Contact: sales@reportsandreports.com for more information.